Fig. 8
Effects of taxifolin treatment on oligomer formation and amyloid-β clearance. Tg-SwDI mice aged 14 months, which received taxifolin for 13 months, exhibited significant decrease in amyloid-β oligomers in the brain and increase of amyloid-β1-40 clearance into the circulation compared with vehicle-treated Tg-SwDI mice, while the levels of amyloid-β1-40 and amyloid-β1-42 in the TBS soluble and insoluble fractions were comparable between vehicle- and taxifolin-treated groups. a–d The amount of amyloid-β1-40, amyloid-β1-42, and amyloid-β oligomers analyzed by ELISA. a The amount of amyloid-β1-40 and amyloid-β1-42 in the TBS soluble fraction. b Amyloid-β oligomers in the soluble fraction. c Amyloid-β1-40 and amyloid-β1-42 in the insoluble fraction (a-c: n = 4–5 each). d The levels of amyloid-β1-40 and amyloid-β1-42 in the blood (amyloid-β1-40: n = 4–6 each, amyloid-β1-42: n = 3 each). Error bars indicate ± SD. *p < 0.05